Respiratory failure & ventilation
Efficacy of solnatide to treat pulmonary permeability edema in SARS-CoV-2 positive patients with moderate to severe acute respiratory distress syndrome (ARDS): A randomized controlled pilot-trial
- stopped early due to slow recruitment
- Stopped early due to slow recruitment; 30 of 40 planned patients included
Authors' conclusion
There was no difference in VFDs or survival between the solnatide and the placebo group. Solnatide appeared safe in this limited cohort of critically ill patients with COVID-19.
Study context
- Population
- Adult mechanically ventilated patients with moderate to severe ARDS (Berlin Definition) caused by COVID-19, two centres in Vienna, Austriaof 40 planned
- Participants
- 30 participants
- Comparison
- Inhaled solnatide 100 mg vs placebo twice daily for 7 days
- Solnatiden = 15
- Placebon = 15reference
- Primary endpoint
- Ventilator-free days (VFDs)
- Follow-up
- Within 28 days
Methodological detailsdouble-blind, pilot, two-centre
- Double-blind
- Pilot
- Two-centre
Primary result
As reported in the abstract
VFDs · 28 days
Solnatide
0
median · days
Placebo
0
median · days
P = 0.653
Secondary outcomes
Survival · day 28
- Survival — Overall survival to day 28: 20 of 30
- 66.7%
Survival · day 60
- One additional death per group until day 60
- 1
Safety
| Outcome | Solnatide | Placebo |
|---|---|---|
| Adverse events (AEs) and serious AEs | ||
| Serious AEs | 10 | 14 |
Adverse events (AEs) and serious AEs
- No AE considered related to study treatment
Original publication
Efficacy of solnatide to treat pulmonary permeability edema in SARS-CoV-2 positive patients with moderate to severe ARDS: A randomized controlled pilot-trial. Anaesth Crit Care Pain Med. Published 23 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →